urologytimes.com/view/study...
"We already know that there are various variables that get reported as part of routine histology reporting, which have a degree of prognostic impact, particularly in the early stage of the disease. But these aren't as powerful in the latest stages of disease, which is affecting the STAMPEDE patients. And so, as part of the study, we partnered with ArteraAI, which, in the localized disease setting has developed a multimodal artificial intelligence model. It's multimodal because it combines both clinical data and digital images of histology slides, and artificial intelligence because we use a deep learning pathway to extract features from both the clinical data and the whole slide imaging data and combine these into a prognostic score that is trained against prostate cancer-specific mortality, which, coincidentally, is the main outcome reported in the STAMPEDE trials."
Basically: AI based system to help the doctors decide if and when to use "heavy weapons" to treat advanced cancer